Monday, April 25, 2016 6:46:04 AM
They were 100% correct for using the below Business Plan model. It fits AMBS's mantra of 'lets make it up as we go along and hype the company in efforts to entice shareholders'.
Rubinfeld was quoted at the Sept., 2014, ASM as stating "were there" regarding LymPro's launch and commercialization. Yet LymPro hasn't even achieved CLIA, let alone AMBS's 'marketing plan' and Gerald stated they were in process of almost 2 years ago. What happened to the marketing plan?
Shame on management and the BOD. IMHO, they're all despicable. In the private sector, they would all have been fired long ago:
Preparing Amarantus for the Up-list in 2H-14: Capital Markets Strategy
Posted on August 10th, 2014
http://www.thechairmansblog.com/amarantus-bioscience/gerald-commissiong/preparing-amarantus-list-2h-14-capital-markets-strategy/
AJMHO
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM